Clinical trial
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected…
NCT00034866 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00034866 |
|---|---|
| Title | Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals |
| Official title | Double-Blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-Experienced Subjects. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Protease inhibitor tipranavir |
| Enrollment | 165 |
| Start date | Apr 1, 2002 |
| Completion | Oct 1, 2002 |
| First posted | May 3, 2002 |
| Last update posted | Sep 20, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: